Zobrazeno 1 - 10
of 71
pro vyhledávání: '"S van der Marel"'
Autor:
Tessa Straatmijer, Vince B.C. Biemans, Marijn Visschedijk, Frank Hoentjen, Annemarie de Vries, Adriaan A. van Bodegraven, Alexander Bodelier, Nanne K.H. de Boer, Gerard Dijkstra, Noortje Festen, Carmen Horjus, Jeroen M. Jansen, Bindia Jharap, Wout Mares, Fiona D.M. van Schaik, Cyriel Ponsioen, Tessa Romkens, Nidhi Srivastava, Michael M.P. J.A. van der Voorn, Rachel West, Janneke van der Woude, Marije D.J. Wolvers, Marieke Pierik, Andrea E. van der Meulen-de Jong, Marjolijn Duijvestein, Malena Schlotter, Martine van Workum, Dirk de Jong, Willemijn van Dop, S. van der Marel, Hayat El Ghabzouri, Kamila Talhaoui, Bas Oldenburg, Nynke Boontje, Herma Fidder, Meike Hirdes, Rob H. Creemers, J. Hoekstra, Jael Smid, Zlatan Mujagic, Marthe François-Verweij, Toos Schakel- van den Berge, Jeroen Maljaars, Rosaline Theeuwen, Denise van den Berg, Suzanne Gerretsen, Xenia Yocarini, Geert D’Haens, Mark Lowenberg, Joep Grootjans, Krisztina Gecse, Gerd Bouma, Petra Waaijenberg, Bart Muskens
Publikováno v:
Clinical Gastroenterology and Hepatology, 21(1), 182-191.e2. ELSEVIER SCIENCE INC
Clinical Gastroenterology and Hepatology, 21, 1, pp. 182-191.e2
Clinical Gastroenterology and Hepatology, 21(1), 182-191.e2. W.B. Saunders Ltd
Clinical Gastroenterology and Hepatology, 21, 182-191.e2
Clinical gastroenterology and hepatology. Elsevier Science
Clinical gastroenterology and hepatology, 21(1), 182-191.e2. W.B. Saunders Ltd
Initiative on Crohn and Colitis 2023, ' Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients : A Nationwide Dutch Registry Study ', Clinical Gastroenterology and Hepatology, vol. 21, no. 1, pp. 182-191.e2 . https://doi.org/10.1016/j.cgh.2022.04.038
Clinical Gastroenterology and Hepatology, 21(1), 182-191.e2. W.B. Saunders
Clinical Gastroenterology and Hepatology, 21, 1, pp. 182-191.e2
Clinical Gastroenterology and Hepatology, 21(1), 182-191.e2. W.B. Saunders Ltd
Clinical Gastroenterology and Hepatology, 21, 182-191.e2
Clinical gastroenterology and hepatology. Elsevier Science
Clinical gastroenterology and hepatology, 21(1), 182-191.e2. W.B. Saunders Ltd
Initiative on Crohn and Colitis 2023, ' Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients : A Nationwide Dutch Registry Study ', Clinical Gastroenterology and Hepatology, vol. 21, no. 1, pp. 182-191.e2 . https://doi.org/10.1016/j.cgh.2022.04.038
Clinical Gastroenterology and Hepatology, 21(1), 182-191.e2. W.B. Saunders
Background & Aims: Clinicians face difficulty in when and in what order to position biologics and Janus kinase inhibitors in patients with anti-tumor necrosis factor-alpha (TNF) refractory ulcerative colitis (UC). We aimed to compare the effectivenes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16c5fd40e67e975df5ce34fd01d6aa67
https://research.rug.nl/en/publications/4d7e144b-6332-47f9-9cee-542a2092238d
https://research.rug.nl/en/publications/4d7e144b-6332-47f9-9cee-542a2092238d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A Fons, V Asscher, A van der Meulen-de Jong, R Stuyt, M Baven-Pronk, S van der Marel, R Jacobs, S Mooijaart, K Kalisvaart, J Maljaars
Publikováno v:
Journal of Crohn's and Colitis. 17:i987-i987
Background Fatigue is a common and debilitating symptom experienced by patients with inflammatory bowel disease (IBD). Studies focusing on fatigue in IBD were conducted in a relatively young population. However, little is known about the prevalence a
Autor:
P W J Maljaars, J E Martens, E van Lingen, M E Tushuizen, D Diaz-Infante Morales, A E van der Meulen-de Jong, M E J Steenhuis, S van der Marel, T van Deynen, Ilse Molendijk
Publikováno v:
International Journal of Colorectal Disease, 37, 349-356. SPRINGER
Purpose Liver steatosis is a frequently reported condition in patients with inflammatory bowel disease (IBD). Different factors, both metabolic and IBD-associated, are believed to contribute to the pathogenesis. The aim of our study was to calculate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cc3b7edc1340a6cf72ab435701a89c9
https://hdl.handle.net/1887/3270955
https://hdl.handle.net/1887/3270955
Autor:
E, van Lingen, M E, Tushuizen, M E J, Steenhuis, T, van Deynen, J, Martens, D Diaz-Infante, Morales, A E, van der Meulen-de Jong, I, Molendijk, S, van der Marel, P W J, Maljaars
Publikováno v:
International journal of colorectal disease. 37(2)
Liver steatosis is a frequently reported condition in patients with inflammatory bowel disease (IBD). Different factors, both metabolic and IBD-associated, are believed to contribute to the pathogenesis. The aim of our study was to calculate the prev
Autor:
J H Arkenbosch, E M J Beelen, G Dijkstra, M Romberg-Camps, M Duijvestein, F Hoentjen, S van der Marel, P W J Maljaars, S Jansen, N K de Boer, R West, C Horjus, L P S Stassen, F van Schaik, O van Ruler, B J H Jharap, N E Erler, M Doukas, A H A G Ooms, G Kats-Ugurlu, J van der Woude, A C De Vries
Publikováno v:
Journal of Crohn's and Colitis. 16:i316-i317
Background In patients with Crohn’s disease (CD), postoperative prophylactic medication based on clinical risk stratification is recommended in international guidelines to prevent recurrence after ileocolonic resection (ICR). This study aimed to ev
Autor:
A Volkers, T Straatmijer, M Duijvestein, A Sales, A Levran, F van Schaik, M Jeroen, K Gecse, C Ponsioen, J Grootjans, J Hanzel, G Tack, J Jansen, F Hoentjen, N de Boer, S van der Marel, G Dijkstra, B Oldenburg, M Löwenberg, A van der meulen, G D’Haens
Publikováno v:
Journal of Crohn's and Colitis. 16:i108-i109
Background Subcutaneous (SC) formulation of vedolizumab (VDZ) is available for Crohn’s disease (CD) and ulcerative colitis (UC). We assessed the efficacy, safety, and pharmacokinetic (PK) profiles of patients with inflammatory bowel diseases (IBD)
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.